9-127843154-G-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_001114753.3(ENG):c.159C>A(p.Cys53*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. C53C) has been classified as Benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_001114753.3 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ENG | NM_001114753.3 | c.159C>A | p.Cys53* | stop_gained | 2/15 | ENST00000373203.9 | NP_001108225.1 | |
ENG | NM_000118.4 | c.159C>A | p.Cys53* | stop_gained | 2/14 | NP_000109.1 | ||
ENG | NM_001406715.1 | c.159C>A | p.Cys53* | stop_gained | 2/8 | NP_001393644.1 | ||
ENG | NM_001278138.2 | c.-388C>A | 5_prime_UTR_variant | 2/15 | NP_001265067.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ENG | ENST00000373203.9 | c.159C>A | p.Cys53* | stop_gained | 2/15 | 1 | NM_001114753.3 | ENSP00000362299.4 | ||
ENG | ENST00000344849.4 | c.159C>A | p.Cys53* | stop_gained | 2/14 | 1 | ENSP00000341917.3 | |||
ENG | ENST00000480266.6 | c.-388C>A | 5_prime_UTR_variant | 2/15 | 2 | ENSP00000479015.1 |
Frequencies
GnomAD3 genomes Cov.: 30
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 30
ClinVar
Submissions by phenotype
Telangiectasia, hereditary hemorrhagic, type 1 Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Aug 28, 2020 | The ENG c.159C>A; p.Cys53Ter variant is reported in the literature in an individual affected with hereditary hemorrhagic telangiectasia (Letteboer 2005). This variant is absent from general population databases (Exome Variant Server, Genome Aggregation Database), indicating it is not a common polymorphism. This variant induces an early termination codon and is predicted to result in a truncated protein or mRNA subject to nonsense-mediated decay. Based on available information, this variant is considered to be pathogenic. References: Letteboer TG et al. Hereditary hemorrhagic telangiectasia: ENG and ALK-1 mutations in Dutch patients. Hum Genet. 2005;116(1-2):8-16. - |
Pathogenic, criteria provided, single submitter | research | NIHR Bioresource Rare Diseases, University of Cambridge | Jan 01, 2018 | PVS1+PM2+PP4 - |
Hereditary hemorrhagic telangiectasia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 28, 2020 | For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in ENG are known to be pathogenic (PMID: 15879500, 20656886, 22385575). This nonsense change has been observed in an individual affected with hereditary hemorrhagic telangiectasia (PMID: 15517393). This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Cys53*) in the ENG gene. It is expected to result in an absent or disrupted protein product. - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 20, 2017 | The p.C53* pathogenic mutation (also known as c.159C>A), located in coding exon 2 of the ENG gene, results from a C to A substitution at nucleotide position 159. This changes the amino acid from a cysteine to a stop codon within coding exon 2. This mutation was identified in one individual with a clinical diagnosis of hereditary hemorrhagic telangiectasia (Letteboer TG et al. Hum. Genet., 2005 Jan;116:8-16). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at